Nicolaas I Bohnen1,2,3,4, Michel J Grothe5,6, Nicola J Ray7, Martijn L T M Müller1,4, Stefan J Teipel5,6. 1. Department of Radiology, University of Michigan, Ann Arbor, MI, USA. 2. Department of Neurology, University of Michigan, Ann Arbor, MI, USA. 3. Veterans Administration Ann Arbor Healthcare System, Ann Arbor, MI, USA. 4. Morris K. Udall Center of Excellence for Parkinson's Disease Research, University of Michigan, Ann Arbor, MI, United States. 5. German Center for Neurodegenerative Diseases (DZNE) - Rostock/Greifswald, Rostock, Germany. 6. Department of Psychosomatic Medicine, University of Rostock, Rostock, Germany. 7. Department of Psychology, Manchester Metropolitan University, Manchester, United Kingdom.
Abstract
PURPOSE OF REVIEW: Although the cholinergic hypothesis of dementia provided a successful paradigm for the development of new drugs for dementia, this hypothesis has waned in popularity. Cholinergic brain imaging may provide novel insights into the viability of this hypothesis. RECENT FINDINGS: Cholinergic receptor and forebrain volumetric studies suggest an important role of the cholinergic system in maintaining brain network integrity that may deteriorate with cognitive decline in Alzheimer disease (AD) and Lewy body disorders (LBD). Bidirectional changes in regional receptor expression may suggest the presence of compensatory responses to neurodegenerative injury. Cholinergic system changes are more complex in LBD because of additional subcortical degenerations compared to AD. Cholinergic-dopaminergic interactions affect attentional, verbal learning and executive functions, and impairments in these two transmitter systems may jointly increase the risk of dementia in Parkinson disease. SUMMARY: The cholinergic hypothesis is evolving from a primary focus on memory toward expanded cognitive functions modulated by regionally more complex and interactive brain networks. Cholinergic network adaptation may serve as a novel research target in neurodegeneration.
PURPOSE OF REVIEW: Although the cholinergic hypothesis of dementia provided a successful paradigm for the development of new drugs for dementia, this hypothesis has waned in popularity. Cholinergic brain imaging may provide novel insights into the viability of this hypothesis. RECENT FINDINGS: Cholinergic receptor and forebrain volumetric studies suggest an important role of the cholinergic system in maintaining brain network integrity that may deteriorate with cognitive decline in Alzheimer disease (AD) and Lewy body disorders (LBD). Bidirectional changes in regional receptor expression may suggest the presence of compensatory responses to neurodegenerative injury. Cholinergic system changes are more complex in LBD because of additional subcortical degenerations compared to AD. Cholinergic-dopaminergic interactions affect attentional, verbal learning and executive functions, and impairments in these two transmitter systems may jointly increase the risk of dementia in Parkinson disease. SUMMARY: The cholinergic hypothesis is evolving from a primary focus on memory toward expanded cognitive functions modulated by regionally more complex and interactive brain networks. Cholinergic network adaptation may serve as a novel research target in neurodegeneration.
Authors: Nils Richter; Inka Allendorf; Oezguer A Onur; Lutz Kracht; Markus Dietlein; Marc Tittgemeyer; Bernd Neumaier; Gereon R Fink; Juraj Kukolja Journal: Neuroimage Date: 2014-06-19 Impact factor: 6.556
Authors: Kai Kendziorra; Henrike Wolf; Philipp Mael Meyer; Henryk Barthel; Swen Hesse; Georg Alexander Becker; Julia Luthardt; Andreas Schildan; Marianne Patt; Dietlind Sorger; Anita Seese; Herman-Josef Gertz; Osama Sabri Journal: Eur J Nucl Med Mol Imaging Date: 2010-11-11 Impact factor: 9.236
Authors: David A Ziegler; Julien S Wonderlick; Paymon Ashourian; Leslie A Hansen; Jeremy C Young; Alex J Murphy; Cecily K Koppuzha; John H Growdon; Suzanne Corkin Journal: JAMA Neurol Date: 2013-02 Impact factor: 18.302
Authors: Nicolaas I Bohnen; Alison J Yarnall; Rimona S Weil; Elena Moro; Mark S Moehle; Per Borghammer; Marc-André Bedard; Roger L Albin Journal: Lancet Neurol Date: 2022-02-04 Impact factor: 44.182